Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay

Glucocorticoid receptor (GR) activity plays a role in many aspects of human physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid tumors. A novel immunohistochemistry (IHC) based assay has been previously developed and validated in order to assess GR immunoreac...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2017-01, Vol.9, p.65-72
Main Authors: Block, Thaddeus S, Murphy, Tiffany I, Munster, Pamela N, Nguyen, Dat P, Lynch, Frank J
Format: Article
Language:English
Subjects:
Apoptosis
Automation
Breast cancer
Cancer therapies
Carcinogenesis
Cell receptors
Cervical cancer
Chemotherapy
Clinical trials
Gene expression
Genetic aspects
Glucocorticoid receptor expression
Glucocorticoids
Health aspects
immunohistochemistry
Kidney cancer
Laboratories
Ligands
Medical prognosis
Nanoparticles
Oncology
Original Research
Ovarian cancer
Prostate cancer
solid tumors
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucocorticoid receptor (GR) activity plays a role in many aspects of human physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid tumors. A novel immunohistochemistry (IHC) based assay has been previously developed and validated in order to assess GR immunoreactivity in triple-negative breast cancer. The current study investigates the standardized use of this validated assay to assess GR expression in a broad range of solid tumor malignancies. Archived formalin-fixed paraffin-embedded tumor bank samples (n=236) from 20 different solid tumor types were analyzed immunohistochemically. Nuclear staining was reported based on the H-score method using differential intensity scores (0, 1+, 2+, or 3+) with the percent stained (out of at least 100 carcinoma cells) recorded at each intensity. GR was expressed in all tumor types that had been evaluated. Renal cell carcinoma, sarcoma, cervical cancer, and melanoma were those with the highest mean H-scores, indicating high levels of GR expression. Colon, endometrial, and gastric cancers had lower GR staining percentages and intensities, resulting in the lowest mean H-scores. A validated IHC assay revealed GR immunoreactivity in all solid tumor types studied and allowed for standardized comparison of reactivity among the different malignancies. Baseline expression levels of GR may be a useful biomarker when pharmaceutically targeting GR in research or clinical setting.
ISSN:1179-1322
1179-1322
DOI:10.2147/cmar.s124475